氨氯地平联合瑞舒伐他汀对不同肥胖类型老年原发性高血压患者的影响

Effect of Amlodipine Combined with Rosuvastatin on Elderly Patients with Essential Hypertension of Different Obesity Types

目的:探究氨氯地平联合瑞舒伐他汀对不同肥胖类型老年原发性高血压患者的影响。方法:选取2022年1—12月于南方医科大学第七附属医院就诊的老年原发性高血压肥胖患者200例为研究对象,根据随机数字表法将其分为腹型肥胖观察组、非腹型肥胖观察组、腹型肥胖对照组和非腹型肥胖对照组,各50例。四组患者均给予氨氯地平治疗,在此基础上,腹型肥胖观察组、非腹型肥胖观察组采用瑞舒伐他汀治疗。比较四组患者体质量指数、动脉硬化指数、血脂、血压和不良反应。结果:治疗后,四组患者体质量指数、动脉硬化指数低于治疗前,非腹型肥胖观察组低于其他三组,差异有统计学意义(P<0.05);治疗后,四组患者总胆固醇、甘油三酯和低密度脂蛋白胆固醇水平低于治疗前,非腹型肥胖观察组低于其他三组,差异有统计学意义(P<0.05);治疗后,四组患者收缩压、舒张压水平低于治疗前,非腹型肥胖观察组低于其他三组,差异有统计学意义(P<0.05);腹型肥胖观察组、非腹型肥胖观察组分别有6例及5例出现轻微头晕、恶心,后自行消退。结论:氨氯地平联合瑞舒伐他汀可降低各型肥胖老年原发性高血压患者血脂、血压,延缓动脉粥样硬化,非腹型肥胖者应用效果较佳,值得临床推广。

Objective:To explore the effect of amlodipine combined with rosuvastatin on elderly patients with essential hypertension of different obesity types.Methods:A total of two hundred elderly patients with essential hypertension and obesity who were treated in the Seventh Affiliated Hospital of Southern Medical University from January to December 2022 were selected as the study objects.According to random number table method,they were divided into abdominal obesity observation group,nonabdominal obesity observation group,abdominal obesity control group and non-abdominal obesity control group,with fifty cases each.All the four groups were treated with amlodipine.On this basis,the abdominal obesity observation group,non-abdominal obesity observation group were treated with rosuvastatin.Body mass index,arteriosclerosis index,blood lipid,blood pressure and adverse reactions were compared among the four groups.Results:After treatment,the body mass index and arteriosclerosis index of the four groups were lower than before treatment,and the non-abdominal obesity observation group was lower than the other three groups,the difference was statistically significant(P<0.05);after treatment,the levels of total cholesterol,triglyceride and low-density lipoprotein cholesterol in the four groups were lower than before treatment,and the non-abdominal obesity observation group was lower than the other three groups,the difference was statistically significant(P<0.05);after treatment,the systolic blood pressure and diastolic blood pressure of the four groups were lower than before treatment,and the non-abdominal obesity observation group was lower than the other three groups,the difference was statistically significant(P<0.05);in the abdominal obesity observation group,non-abdominal obesity observation group,6 cases and 5 cases showed slight dizziness and nausea,which subsided spontaneously.Conclusion:Amlodipine combined with rosuvastatin can reduce blood lipids and blood pressure in all types of obese elderly patients with essential hypertension and delay atherosclerosis,and the application effect is better in non-abdominal obese patients,which is worthy of clinical promotion.